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We have previously demonstrated that chordomas
express activated platelet-derived growth factor receptor
(PDGFRB) and that treatment with imatinib, which is
capable of switching off the activation of various recep-
tor tyrosine kinases (RTKs) including PDGFRB, benefits
a number of patients. The aim of this study was to ident-
ify the possible presence of other activated RTKs and
their downstream signaling effectors. Cryopreserved
material from 22 naı¨ve sporadic chordomas was investi-
gated for the presence of activated RTKs and their
cognate ligands and downstream signaling effectors by
means of human phospho-RTK antibody arrays,
Western blotting, and molecular analysis; immunohisto-
chemistry and fluorescence in situ hybridization were
used to analyze the corresponding formalin-fixed and
paraffin-embedded samples. We detected activated
PDGFRB, FLT3, and colony stimulating factor 1 recep-
tor (CSF1R) of the PDGFR family and highly phos-
phorylated EGFR, HER2/neu, and (to a lesser extent)
HER4 of the EGFR family. The detection of
PDGFRB/PDGFB confirmed our previous data. The
presence of activated EGFR was paralleled by the
finding of high levels of epidermal growth factor (EGF)
and transforming growth factor a (TGFa) and PDGFB
co-expression and PDGFRB co-immunoprecipitation.
Of the downstream effectors, the PI3K/AKT and
RAS/MAPK pathways were both activated, thus
leading to the phosphorylation of mammalian target of
rapamycin (mTOR) and 4E-BP1 among the regulators
involved in translational control. Taken together, our
results (i) provide a rationale for tailored treatments tar-
geting upstream activated receptors, including the
PDGFR and EGFR families; (ii) support the idea that a
combination of upstream antagonists and mTOR inhibi-
tors enhances the control of tumor growth; and (iii) indi-
cate that the 4E-BP1/eIF4E pathway is a major regulator
of protein synthesis in chordoma.
Keywords: chordomas, mTOR, receptor tyrosine
kinases (RTKs), signal transduction.
C
hordomas are rare low-grade bone tumors that
account for 1%–4% of all malignant bone
tumors;1 they arise from the sacrum in 50%–
60% of cases, from the skull base in 20%–35%, from
the cervical vertebrae in 10%, and from the thoraco-
lumbar vertebrae in 5%.2 Their peak incidence is
between the fourth and sixth decades of life, although
children may also be affected (5%). The M:F ratio is
2–3:1 (more males are affected by sacral chordomas,
whereas the frequency of chordomas of the skull
base seems to be the same in men and women).3
Chordomas are generally sporadic, but there have also
been familial cases4–6 and tumors arising in patients
with tuberous sclerosis complex (TSC).7–11
Untreated disease has an indolent but relentless
course. The tumors are locally highly aggressive and
may also give rise to distant metastases (10%–30% of
cases, or more). On a population basis, the reported 5-
and 10-year survival rates are about 70% and 40%,
which reflects the naturally slow progress of the
disease; however, after the development of metastases,
median survival is about 1 year.3
Surgery remains the best standard treatment for both
localized and metastatic disease; radiotherapy can
†Some of the data were presented at the Second International
Chordoma Research Workshop, NIH Bethesda, April 3–5, 2008 and at
the 2nd ESMO International Symposium on Soft Tissue Sarcoma and
GISTs, Milan, Italy, May 13–14, 2008.
‡These authors contributed equally to the study.
Corresponding Author: Elena Tamborini, PhD, Experimental
Molecular Pathology, Department of Pathology, Fondazione IRCCS
Istituto Tumori Milano, Via G. Venezian 1, 20133 Milano, Italy (elena.
tamborini@istitutotumori.mi.it).
Received April 21, 2009; accepted December 27, 2009.
Neuro-Oncology 12(8):776–789, 2010.
doi:10.1093/neuonc/noq003 NEURO-ONCOLOGY
Advance Access publication February 17, 2010
#The Author(s) 2010. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights
reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/article-abstract/12/8/776/1073838 by U
niversita degli Studi di M
ilano user on 17 M
ay 2019
control tumor growth, particularly cobalt or heavy
particle radiation, but the high doses required lead to
significant toxicity, and standard cytotoxic chemo-
therapy is inefficacious.3 Targeted molecular therapy
recently been found to be promising as imatinib has
induced an anti-tumor response in a number of
patients when used alone12 and when combined with
cisplatin in patients showing secondary progression
on imatinib montherapy.13 Furthermore, combined
treatment with imatinib and sirolimus has proved
to be effective in patients with imatinib-resistant
chordomas.14
We have previously demonstrated that chordomas
express activated platelet-derived growth factor receptor
(PDGFRB) and that this activation is due to the occur-
rence of an autocrine/paracrine loop;15 it has also
been reported that a subset of chordomas express
EGFR and c-MET.16 The presence of activated receptor
tyrosine kinases (RTKs) leads to the activation of sec-
ondary transducers belonging to the MAPK or PI3K/
AKT pathways, which together activate mTOR;17
downstream of mTOR, S6K/S6, and 4E-BP1 harmonize
protein synthesis, and promote cell growth and
proliferation.
Recent insights into the regulation of translation
control have shown that, in addition to the p70 riboso-
mal S6 kinase (p70S6K)-mediated PI3K/mTOR
pathway, S6 may also be regulated by the p90 ribosomal
S6 kinase (p90RSK)-mediated RAS/MAPK cascade.18
Furthermore, 4E-BP1 (a repressor of eIF4E) may be inac-
tivated as a result of hyper-phosphorylation by the
PI3K/mTOR or RAS/MAPK cascade through a still uni-
dentified mechanism (which abrogates the association
between 4E-BP1 and eIF4E),19 or as a result of transcrip-
tion silencing20,21 (Fig. 1). More importantly, S6 may act
as an oncogene or tumor suppressor gene.22,23 Finally, it
is likely that the specific functions of the 2 regulators of
the translational machinery are closely related to cell
type or tumor histotype.24
In this study, human phospho-RTK antibody arrays
(RTK cards) were used to explore the upstream RTK
profile of 7 naı¨ve sporadic chordomas, and detected
activated PDGFRB, FLT3, and colony stimulating
factor 1 receptor (CSF1R) of the PDGFR family, as
well as highly phosphorylated EGFR, HER2/neu,
and (to a lesser extent) HER4 of the EGFR family.
Taken together, this subsequently validated upstream
analysis indicates that both the PDGFR and EGFR
families may be activated in chordomas. This
upstream analysis was extended to 22 sporadic cases,
and downstream effectors were investigated. We
found activated PI3K/AKT and RAS/MAPK cascades
lead to the phosphorylation of mTOR. The absence
of gene deregulation upstream of mTOR in the pres-
ence of PDGFRB and EGFR ligands supports the
hypothesis that the activation is ligand dependent
and that combined RTK and mTOR/MAPK inhibi-
tors25 may lead to better disease control. Our findings
also indicate that translational control downstream of
mTOR is preferentially driven by the 4E-BP1/eIF4E
pathway.
Materials and Methods
Clinical Data and Materials
We analyzed 21 surgical specimens and 1 wide biopsy
sample taken from 22 surgically treated patients with a
confirmed diagnosis of conventional sporadic chor-
doma: 16 males and 6 females with a median age of
61 years (range 36–77). Fourteen were primary
tumors and 8 were recurrences (Patients 7, 10–12, 14,
19, 20, and 22); 18 were located in the sacrum and 4
in the thoraco-lumbar vertebrae. Freshly frozen material
and formalin-fixed paraffin-embedded (FFPE) blocks
were available for all but 1 of the patients (Patient 14),
for whom there was only frozen material.
All of the analyses involved representative areas of
tissue sections carefully selected under microscope
control in order to avoid normal tissue or necrosis.
The biochemical and molecular analyses were per-
formed using representative cryopreserved tissue and
checking 1 hematoxylin-and-eosin-stained frozen
section; the immunohistochemical (IHC) and fluor-
escence in situ hybridization (FISH) analyses were
performed using the corresponding FFPE samples.
Written informed consent was obtained from all of
the patients.
Analyses of Frozen Material
Biochemical Analysis.—RTK Phosphorylation Array.
The expression of phosphorylated growth factor RTKs
was detected using the Proteome Profiler Array Kit
(ARY001, R&D Systems) as laid down in the manufac-
turer’s protocol, and 2 mg of protein lysate per array.
Total Protein Extraction, Immunoprecipitation
and Western Blotting: The proteins were extracted
from tissue samples stored at 2808C as previously
described.26 For the immunoprecipitation (IP) analysis,
1 mg each of protein lysates was precipitated by means
of incubation with Protein A Sepharose (Amersham
Biosciences) and specific antibodies: 20 ml of rabbit
polyclonal anti-PDGFRB (sc-432, Santa Cruz
Biotechnology), 10 ml of rabbit polyclonal anti-EGFR
(sc-120, Santa Cruz Biotechnology), and 10 ml of
mouse monoclonal anti-Her2/Neu (Ab-3, Calbiochem;
MGR2 kindly provided by Dr. Tagliabue, Fondazione
IRCCS Istituto Nazionale dei Tumori, Milan, Italy).
Immunoblotting was performed using the anti-
phosphotyrosine mouse monoclonal antibody (05–321,
Upstate) diluted 1:3000 to reveal the absence or presence
of activated/phosphorylated receptor. The filters were
stripped and then incubated with the specific antibody
in order to detect the degree of receptor expression:
anti-PDGFRB (sc-432, Santa Cruz Biotechnology),
anti-EGFR (sc-03, Santa Cruz Biotechnology), and
anti-HER2/neu (Ab-3, Calbiochem). The filter of IP
anti-PDGFRB was stripped again and incubated
with anti-PI3-kinase p85a (sc-1637, Santa Cruz
Biotechnology); the filters of IP anti-EGFR were incu-
bated with anti-PDGFRB and/or anti-HER2/neu in
order to detect the co-immunoprecipitated proteins.
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For the EGFR IP/WB experiments, the protein bands
detected on filters were densitometrically analyzed on
X-ray film images using Quantity One Software
(Bio-Rad). The densitometrically determined levels of
phosphorylated EGFR were calculated as ratios of phos-
phorylated and expressed EGFR.
The expression and activation of the downstream
targets were detected by means of direct Western
blotting (WB) after loading 20 mg of total protein/lane
using the antibodies anti-P-AKT (#4058S Ser473,
Cell Signaling Technology), anti-AKT (#9272, Cell
Signaling Technology), anti-P-MAPK (#4376S Thr202/
Tyr204, Cell Signaling Technology), anti-MAPK (#9102
p44-42, Cell Signaling Technology), anti-P-mTOR
(#2971S Ser2448, Cell Signaling Technology), anti-
mTOR (#2972, Cell Signaling Technology), anti-P-S6
(#2215 Ser240/244 and #2211 Ser 235/236, Cell
Signaling Technology), anti-P-4E-BP1 (#9455 Thr70,
Cell Signaling Technology), anti-4E-BP1 (#9644
Cell Signaling Technology), anti-PTEN (#9559, Cell
Signaling Technology), and anti-actin (A2066, Sigma).
The negative control for PTEN WB was a cell line
without PTEN protein expression (3962 M, kindly pro-
vided by Dr. Rodolfo, Fondazione IRCCS Istituto
Nazionale dei Tumori).27
RNA Extraction and Real-Time PCR.—Total RNA was
extracted from fresh frozen tissue and reverse tran-
scribed as previously described.28
RTK Ligand Detection. The presence or absence of
EGFR ligand mRNA [EGF and transforming growth
factor a (TGFa)] was verified by means of real-time
PCR using specific EGF (Hs00153181_M1) and TGFa
probes (Hs00608187_M1) (Applied Biosystems);
Table 1 shows the experimental conditions. The
mRNA was not quantified.
PTEN and S6. Real-time PCR of PTEN and S6 was per-
formed on respectively, 4 and 6, representative samples
using specific PTEN (Hs02621230_S1) and S6 probes
(Hs01058685_g1), and the experimental conditions
shown in Table 1.
DNA Extraction and Sequencing.—DNA was digested
by proteinase-K and underwent standard phenol extrac-
tion. Mutation analyses were made of exons 18–21 of
EGFR, exons 9 and 20 of PI3KCA, exons 5–9 of
PTEN, exons 1 and 2 of KRAS, and exons 11 and 15
of BRAF. Table 1 shows the primers and experimental
conditions used for PCR amplification. After purifi-
cation using the ExoSAP-IT Kit (USB Amersham), the
DNA of the PCR products was automatically sequenced
(ABI prism 377; Applied Biosystems).
Analyses of FFPE Material
RNA Extraction and RT-PCR.—Total RNA from
microdissected samples was isolated by means of the
Fig. 1. Usual regulation of RTK downstream effectors. The grey lines indicate new pathways related to protein activation/inhibition by
means of phosphorylation (thick continuous lines) or transcriptional silencing (dotted lines). In addition to being phosphorylated by
p70S6K/mTOR, S6 may be activated by p90RSK. The same is true of 4E-BP1 which, in addition to mTOR, may be phosphorylated by
an unknown factor (light-grey thick continuous lines); it may also be regulated by the transcriptional silencing induced by MAPK and/or
PI3K (light-grey thick dotted lines). Insert: Non-phosphorylated 4E-BP1 forming a complex with eIF4E that blocks protein translation.
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Table 1. Experimental condition
Real-time PCR
Ligands Probes Conditions
EGF Hs00153181_M1 (Applied Biosystem) 508C 20 –958C 100 –958C 150, 608C 10  40 cycles
TGFa Hs00608187_M1 (Applied Biosystem)
PTEN Hs02621230_S1 (Applied Biosystem)
S6 Hs01058685_g1 (Applied Biosystem)
Molecular analysis
Gene Exon Sense Antisense Annealing temperature (8C)
EGFR 18 ctgaggtgacccttgtctc tacagcttgcaaggactctg 60  40 cycles
19 agatcactgggcagcatgtg cagctgccagacatgagaa
20 cttctggccaccatgcgaa ccaggcaaactctgctatcc
21 tcttcccatgatgatctgt cctggtgtcaggaaaatgct
PI3K 9 gggaaaaatatgacaaagaaagc ctgagatcagccaaattcagtt 58  35 cycles
20 ctcaatgatgcttggctctg tggaatccagagtgagctttc
PTEN 5 tgcaacatttctaaagttacctact gaggaaaggaaaaacatcaaaaa 55  40 cycles
6 tttttcaatttggcttctcttttt tgttccaatacatggaaggatg
7 cagttaaaggcatttcctgtg ttttggatatttctcccaatgaa
8 tgtcatttcatttctttttcttttc aagtcaacaacccccacaaa
9 tcatggtgttttatccctcttg tgagtcatatttgtgggtttca
K-Ras 1 tggtggagtatttgatagtgt catgaaaatggtcagaga 56  35 cycles
2 ggtgcactgtaataatccagac tgatttagtattatttatggc 50  45 cycles
B-Raf 11 tccctctcaggcataaggtaa cgaacactgaatatttcctttgat 55  40 cycles
15 tcataatgcttgctctgatagga ggccaaaaatttaatcagtgga 56  40 cycles
Immunohistochemical analysis
Antibody Clone Company Dilution Antigen retrieval Positive control
PDGFRB sc-339 Santa Cruz Biotecnology 1:100 60 at 958C mM citrate buffer, pH 6 Human breast carcinoma
EGFR K1492 Dako Procedures performed in accordance with manufacturer’s protocol
Her2 Polyclonal Dako 1:2000 60 at 958C, pH 6 Human breast carcinoma
TGFa, transforming growth factor a.
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TRIzol method (Invitrogen), and reverse transcribed
using Superscript reverse transcriptase (Invitrogen) and
both oligo dT and random hexamers.
Ligand Detection: The presence of PDGFB mRNA
was verified by means of RT-PCR as previously
described.28
Immunohistochemistry.—The antibodies and exper-
imental conditions are shown in Table 1. The score for
each marker is listed below.
PDGFRB. Cytoplasmic immunoreactivity was evalu-
ated and scored on the basis of the percentage of
immunoreactive cells (not less than 70%). PDGFRB
staining intensity was evaluated using vessel wall immu-
noreactivity as an in-built control.
EGFR. The score was applied according to the manufac-
turer’s instructions, combining the scores relating to
staining intensity and the percentage of immunopositive
cells.29 The resulting low, intermediate, or high/strong
immunodecoration are reported in Table 2. In the
cases scored as negative, none of the cells were
immunodecorated.
HER2/neu. The same parameters considered for
PDGFRB were applied for this receptor. As for EGFR,
in the cases scored as negative, none of the cells were
positive.
For all these markers, the inter-observer correlation
for the assessment of the staining was concordant
(100%).
Fluorescence in Situ Hybridization.—Fluorescence in
situ hybridization analyses were used to investigate the
gene status of EGFR, HER2/neu, PTEN, and S6 as
previously described.26,30,31 In particular, the BAC
clones RP11-126H20 and RP11-624N8 were used as
probes for S6, and Spectrum Green(SG)-labeled CEP9
(Vysis) was used as the control probe. The dual-color
FISH mixture was prepared using Spectrum Orange
(SO)-labeled S6þ SG-labeled CEP9. The corresponding
gene status was evaluated as previously described.32 To
simplify the FISH/IHC correlations, the high EGFR and
HER2/neu polysomy/amplification group was classified
as FISH positive (FISH þ ), and the remaining groups
(disomy, trisomy, or low polysomy) as FISH negative
(FISH2), whereas the PTEN and S6 gene status patterns
and loss/gain percentages were detailed in each case.
Results
The profiles of the 8 recurrent tumors were almost iden-
tical to those of the 14 primary tumors. All of the data
are summarized in Table 2.
Upstream Targets
RTK Array Assays.—The RTK array experiments used
the 7 chordomas for which adequate total protein
extract was available (Patients 1, 4–6, 8, 12, and 13).
RTK activation was evaluated by comparing the inten-
sity of the labeled spots relating to each tumoral
protein extract with that of those relating to the positive
and negative controls on the array membrane.
All 7 patients showed activated PDGFRB (although
the level of activation was low in case Patient 13) and,
to a lesser extent, FLT3 and CSF1R of the PDGFR
family. EGFR was highly activated in 4 patients
(Patients 1, 4, 12, and 13), activated in 2 (Patients 5
and 6), and negative in 1 (Patient 8). HER2/neu was
detected in 5 cases (Patients 1, 4, 5, 12, and 13), and
HER4 in 3 (Patients 4, 5, and 12). Of the “non-
druggable” RTKs, Axl and Dtk were activated in all of
the patients. The negative controls were always
undetectable. Figure 2A shows 4 representative cases
(Patients 4, 5, 12, and 13). Overall, the profiles of the
42 RTKs evaluated on the array membrane indicated sig-
nificant activation of members of the PDGFR family
(PDGFRB, FLT3, and CSF1R) and the EGFR families
(EGFR, HER2/neu, and HER4).
Confirmatory Biochemical Analysis of PDGFRB,
EGFR, and HER2/Neu.—All of the case material was
analyzed by means of IP/WB in order to confirm the
RTK array data. PDGFRB was activated in all but 1
case, in line with our previous data,15 whereas EGFR
was activated in 17 and not activated in 5 (Patients 1
and 8–11); Fig. 2B shows 12 representative cases. The
results obtained using the 2 methods perfectly over-
lapped, except in Patient 1. The EGFR WB results
were quantified by densitometry in order to define the
activation level of the receptor more precisely (Fig. 2C).
Total protein extracts from 6 cases expressing acti-
vated EGFR (Patients 2, 4, 12, 13, 15, and 18) were
immunoprecipitated with anti-EGFR and then incubated
with anti-PDGFRB: PDGFRB co-immunoprecipitated
with EGFR in all cases (Fig. 2D).
Immunoprecipitation and Western blotting analysis
of HER2/neu using antibody directed against the NH2
terminal showed that all of the cases were negative,
which is consistent with the unrecognizable structural
conformation of the receptor’s extracellular domain.
However, an antibody specific for the C-terminal
applied to the 14 cases for which material was still avail-
able revealed HER2/neu expression/phosphorylation in
4 cases (Patients 4, 5, 15, and 18) and HER2/neu
expression alone in 2 (Patients 17 and 20). The IP/WB
and array data matched in 4 cases (Patients 4–6 and 8)
and did not match in 2 (Patients 12 and 13); insufficient
material prevented a comparison in 1 case (Patient 1).
The stripped membranes with EGFR immunoprecipi-
tated proteins were re-incubated with a HER2/neu anti-
body, which revealed the presence of HER2/neu in 9/22
cases, thus suggesting that the 2 members of the family
may be involved in heterodimers. The result was con-
firmed by further incubation of the stripped filter with
the EGFR/PDGFRB co-IP experiment (Fig. 2D, upper
panel) and with anti-HER2/neu antibody (Fig. 2D,
lower panel).
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Table 2. Summary results
Upstream marker and method
PDGFRB PDGFB EGFR EGF TGFa Her2/neu
Cases RTK array IP/WB IHC RT-PCR RTK array IP/WB IHC FISH Real-time PCR Real-time PCR RTK array IP/WB IHC FISH
1 þ þP þ þ þ 2 2 2 þ þ þ 2 2
2 þP þ þ þP 2 2 þ þ 2 2
3 þP þ þ þP þM 2 þ þ 2 2
4 þ þP þ þ þ þP þS þ þ þ þ þP 2 þ
5 þ þP þ þ þ þP 2 NE þ þ þ þP 2 NE
6 þ þP þ þ þ þP 2 þ þ þ 2 2 2 þ
7 þP þ þ þP 2 þ þ þ 2 þ
8 þ þP þ þ 2 2 2 2 þ þ 2 2 2 2
9 þP þ þ 2 2 2 þ þ 2 2
10 þP þ þ 2 2 2 þ þ 2 2
11 þP þ þ 2 NE 2 þ þ 2 2
12 þ þP þ þ þ þP 2 NE þ þ þ 2 2 NE
13 þ þP þ þ þ þP þS 2 þ þ þ 2 2 2
14 þP þ þP þ þ 2
15 þP þ þ þP 2 2 þ þ +P 2 2
16 2 þ þ þW 2 2 þ þ 2 2 2
17 þP þ þ þW 2 2 þ þ + 2 2
18 þP þ þ þP þL 2 þ þ þP 2 2
19 þP þ þ þP þS 2 þ þ 2 2 þ
20 þP þ þ þP þM 2 þ þ þ 2 2
21 þP þ þ þP þS NE þ þ NE NE
22 þP þ þ þP 2 2 þ þ 2 2 2
Continued
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Table 2. Continued
Downstream marker and method
P85 AKT PTEN ERK 1/2 mTOR S6 PS6 Thr240/244 PS6 Thr235/236 S6 4EBP1
Cases IP/WB WB WB FISH Real-time WB WB WB WB WB FISH Real-time WB
1 þ þP þ M(80) þ þP þP þ 2 +P D þ þP
2 þ þP þ D þ þP þP þ +P +P D þP
3 þ þP þ M(70) þ þP þP þ +P +P D þ þP
4 þ þP þ HP þP þP þ þP þP D þ þP
5 þ þP þ NE þP þP þ +P þP NE þP
6 þ þP þ HP(10) þP þP 2 2 2 D þ þP
7 þ þP þ M(50) þP þP + 2 +P D þ
8 þ þP þ D þ þP 2 2 2 2 LP þ þP
9 þ 2 2 D þP +P 2 2 2 D þ
10 þ þP þ M(50) þP þP þ +P 2 D þ þP
11 þ þP þ D þP þP 2 2 2 þ
12 þ þP þ M(50) þP þP þ +P þP þP
13 þ þP þ D þP þP + 2 +P D þP
14 þ þP þ þP þP þ +P þ
15 þ þP þ D þP þP þ +P M þP
16 2 þP þ D þP þP 2 2 D þ
17 þ þP þ M(60) þP þP þ +P NE þ
18 þ þP þ D þP þP 2 2 D þP
19 þ þP þ D þP þP 2 2 D +
20 þ þP þ M(90) þP þP þ +P D þP
21 þ þP þ NE þP þP 2 2 NE 2
22 þ þP þ D þP þP þ +P þ
The empty spaces correspond to not performed analyses. Abbreviations: IP, immunoprecipitation; WB, Western blotting; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; NE,
not evaluable; P, phosphorilated; W, weak; D, disomic; HP, high polisomy (percentage); M, monosomic (percentage). For EGFR IHC: S, strong; M, moderate; L, low.
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Fig. 2. Expression and activation of RTKs. The sample numbers correspond to the cases listed in Table 2. (A) RTK arrays. Equal amounts of
total protein extracts from 4 representative cases were incubated with the arrays. The rectangles indicate the presence of activated receptors.
(B) EGFR IP/Western blot analysis of 12 representative cases. To confirm the presence of activated EGFR, proteins were immunoprecipitated
with a specific antibody and blotted onto a membrane. The anti-pTyr panel identified the phosphorylated EGFR; the anti-EGFR panel
indicates the expression of the corresponding receptor. The A431 cell line (American Type Culture Collection, Manassas, VA) was used
as the positive control. (C) Densitometric analysis of levels of EGFR activation. The bands representing phosphorylated EGFR and total
EGFR levels were quantified, and the ratios between phosphorylated and expressed EGFR were calculated, the ratio relating to the A431
cell line (positive control) was 0.97. The low level of phosphorylation detected in samples #16 and #17 may have been due to
methodological problems (non-optimal cryopreservation). (D) Co-IP of EGFR/PDGFRB and EGFR/HER-2/neu. Total protein extracts from
6 EGFR-positive cases were immunoprecipitated with anti-EGFR antibody and run on a gel. The filter was incubated with anti-PDGFRB
antibody, then stripped and re-incubated with anti-HER2/neu antibody. Extracts from the 2N5A cell line (immunoprecipitated with
anti-PDGFRB) and SKBR3 cell line (immunoprecipitated with anti-HER2/neu) were respectively used as positive controls for PDGFRB and
HER2/neu protein. The 2N5A cell line (derived from the NIH3T3 cell line and expressing the COL1-PDGFB fusion that characterized
dermatofibrosarcoma protuberans) was kindly provided by Dr. Greco, Fondazione IRCCS Istituto Nazionale dei Tumori; the SKBR3 came
from the American Type Culture Collection.
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Analysis of the Mechanisms Sustaining PDGFRB and
EGFR Activation.—We have previously demonstrated
the absence of PDGFRB-activating mutations in chordo-
mas;15 in this study, we analyzed the EGFR gene to
exclude a mutation-based activation mechanism.
EGFR was wild type in all of the samples.
Real-time PCR showed that all of the cases highly
expressed both EGFR ligands (EGF and TGFa) and as
expected,15 PDGFB mRNA was expressed in all of the
analyzed cases (Table 2). We thus concluded that,
most likely, the activation of these 2 receptors is sus-
tained by an autocrine/paracrine loop.
Downstream Effectors
We biochemically and/or molecularly investigated the
PI3K/AKT (the p85 and p110 subunits of PI3K, AKT,
and PTEN) and MAPK pathways (RAS, BRAF, and
Erk1/2), and then analyzed the mTOR kinase and its
S6 and 4E-BP1 downstream effectors. The analysis of
PTEN and S6 was complemented by the FISH analysis
of FFPE material.
All of the data are summarized in Table 2.
PI3K/AKT Pathway.—As a first confirmatory step of
receptor activation, we verified the binding of the p85
subunit of PI3K to activated PDGFRB: co-IP was
detected in all of the samples. The p110 subunit gene
(PI3KCA) was investigated by looking for activating
mutations, and the hot spots corresponding to exons 9
and 20 were sequenced; no mutations were detected in
any of the cases.
Western blotting showed that AKT was activated to
different extents in all of the analyzed samples (Fig. 3A
upper panel), except Patient 9.
PTEN phosphatase reverses the effects of p110-PI3K.
We sequenced the mutation hot spot (from exon 5 to
exon 9) but did not detect any alterations.
As gene copy number is 1 of the mechanisms responsible
for PTEN destabilization, we used FISH to analyze
matched FFPE samples and found alterations in 9 (47%)
of the 19 successfully analyzed cases: chromosome 10
monosomy in 7 cases (1 of which is shown in Fig. 3B) and
a high degree of polysomy in 2 cases. However, WB evalu-
ating the overall expression of PTEN protein indicated no
differences in expression levels (Fig. 3C; the results were
validated using a cell line null for PTEN expression).
Given the discrepancy between the FISH analysis and
protein expression, we further analyzed PTEN mRNA
expression in2disomic (Patients2and8)and2monosomic
cases (Patients 1 and 3); the biochemical results were con-
firmed by real-time PCR as no differences were found
between the monosomic and disomic cases (Fig. 4D).
MAPK Pathway.—Analysis of the KRAS and BRAF
mutation hot spots revealed no activating mutations.
Direct WB showed that both p44 and p42 (Erk1/2)
were much more highly expressed and phosphorylated
than any other of the analyzed proteins (Fig. 3A lower
panel).
mTOR, S6, and 4E-BP1.—mTOR is activated by both
pathways and, as both cascades are activated in chordo-
mas, we expected to find an activated kinase in all
22 samples. WB revealed a phosphorylated protein in
all but 2 cases (Patient 9 was only weakly positive;
Patient 8 was negative) (Fig. 4A).
The activation status of S6 was investigated using
Ser235–236 and Ser240–244 phospho-antibodies.
Ser240–244 residues are preferentially phosphorylated
in response to the mTOR/PI3K pathway, and S6 was
found to be expressed and activated to a low/very low
extent in 11 cases, not expressed in 8, and expressed but
not phosphorylated in 3 (Fig. 4B). The same trend (a low
level of activation) was observed in the 13 cases that
were analyzed using the Ser235–236 antibody, which
also detects the residues phosphorylated in response to
the mTOR-independent RAS/MAPK pathway.
As the low level of protein expression/activation
despite mTOR activation suggested that S6 plays an
oncosuppressing role, we used FISH (on FFPE material)
and real-time PCR to ascertain its gene status and
mRNA expression. The FISH results showed that all
but 1 of the analyzed cases had a disomic or low polyso-
mic pattern (Patient 15 was monosomic, with positive
protein expression). However, it is possible that our
probe does not detect the very small 3979 bp deletion
of the S6 gene,33 and that the loss in Patient 15 (which
also carried monosomy of the p16 gene closely
mapping on the same chromosome; data not shown)
was attributable to a longer deletion encompassing
both genes, although a second probe gave the same
results (data not shown). Nevertheless, real-time PCR
showed the same level of S6 transcript in the samples
with (Patients 1, 3, 4, and 10) and without S6 protein
expression (Patients 6 and 8).
To investigate 4E-BP1, we used the Thr70 phospho-
antibody to highlight protein hyper-phosphorylation,
which, by abrogating the association between 4E-BP1
and eIF4E, releases translational repression. 4E-BP1
was hyper-phosphorylated in 13 cases, not expressed in
1, and expressed but not phosphorylated in 8 (Fig. 4C),
which means that eIF4E was released in 14 cases, thus
favoring protein synthesis, cell proliferation, and tumor
progression. In 4 cases (Patients 9, 11, 16, and 19),
4E-BP1 was expressed but not phosphorylated (and
thus eIF4E was repressed), and the fact that S6 was null
supports the hypothesis that malignant progression may
be sustained by the absence of S6, which may act as an
oncosuppressing gene as it does in chondrosarcomas.23
The level of S6 activation was low in the remaining 4
cases in which eIF4E was repressed (Patients 7, 14, 17,
and 22). In Patient 8, in which 4E-BP1 was hyper-
phosphorylated in the absence of mTOR activation and
Ser235–236/240–244 S6 phosphorylation, it is possible
to assume activation through the RAS/MAPK cascade
mediated by a still unknown factor,19 although many
oncogenic events may lead to 4E-BP1 phosphorylation.34
Taken together, our findings downstream of mTOR
suggest that both PI3K/AKT and RAS/MAPK signaling
are involved in regulating protein transduction and that
the 4E-BP1 pathway drives protein synthesis, whereas
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Fig. 3. Expression of downstream signaling markers. (A) Western blots showing the presence of phosphorylated/activated and total AKT and
ERK1/2. PTEN analyses: (B) FISH. The chromosome 10 probe is labeled with Spectrum Green and the PTEN locus-specific probe with
Spectrum Orange. Case 1: monosomic PTEN in 80% of the cells. Case 2: disomic PTEN. (C) Western blotting. PTEN expression in 12
representative monosomic or disomic cases: monosomic cases were Patients 1, 3, 7, 12, and 17. The different electrophoretic mobility
observed in Patient 16 may have been due to protein hyper-phosphorylation, which cannot be confirmed by the antibody used because
it does not discriminate between phosphorylated and non-phosphorylated PTEN. The A431 and 3962 M cell lines were, respectively,
used as positive and negative controls, and anti-actin antibody was used to normalize the results. (D) Real-time PCR in the disomic and
monosomic cases. Lymphocyte mRNA was used for calibration purposes.
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the hypothesized oncosupprossing role of S6 remains
undetermined and will require further experiments.
Methods of Selecting Patients for Possible Targeted
Treatments.—Our previous positive experience with
PDGFRB immunophenotyping in chordoma,15 and
the recent favorable results obtained in non-small cell
lung cancer using gene and protein profiling,35,36
prompted us to find a screening method capable of
identifying predictive markers for TK inhibitors that can
be easily applied to FFPE samples (frozen material is not
frequently available). To this end, we investigated the sen-
sitivity of IHC and FISH analyses (alone or combined),
taking the biochemical results as the gold standard.
IHC. In all the cases (100%), more than 80% of the cells
showed PDGFRB cytoplasmatic immunoreactivity, with
the intensity of the staining being stronger than that of
the vessel wall used as the control.
EGFR was expressed in 7/20 cases (4 classified as
strong, 2 as moderate, and 1 as low) showing a decora-
tion mainly related to the cell membrane. In the
remaining cases, scored as negative, none of the
tumoral cells were positive for EGFR.
All cases were negative for HER2/neu as all tumor
cells were negative.
FISH. As amplification is one of the mechanisms respon-
sible for receptor activation in the case of EGFR family
genes, we used FISH to analyze the EGFR and HER2/
neu genes. Of the 18 evaluable cases, the EGFR gene
was disomic in 11 and low polysomic in 4 (Patients 10
and 17–19) (FISH2) and high polysomic in 3
(Patients 4, 6, and 7) (FISHþ).
The HER2/neu gene was disomic in 10 and low poly-
somic in 4 (Patients 10, 11, 17, and 18) (FISH2), and
was high polysomic in 3 (Patients 4, 7, and 19) or ampli-
fied in some areas (Patient 6) (FISHþ).
All 7 cases with deregulated EGFR also showed
deregulated HER2/neu; they all also had the same
deregulation pattern except for Patients 19 and 6.
Correlations Between IP/WB, IHC, and FISH.—
EGFR. We compared the IP/WB results with those of
IHC and FISH in 17 evaluable patients. The IP/WB and
Fig. 4. mTOR expression and its downstream effectors. mTOR (panel A), S6 (panel B), and 4E-BP1 (panel C) in the same 12 representative
cases analyzed and reported in Figure 3, panel A. Twenty micrograms of total protein extract was loaded for each sample. The A431 cell line
was used as the positive control and anti-actin antibody was used to normalize the results.
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IHC data correlated in 9 cases: in particular, all of the IP/
WB-negative cases were confirmed by IHC, whereas only
5 of the 13 IP/WB-positive cases (38%) were also IHC
positive, thus indicating that IHC is less sensitive than
IP/WB but does not generate false positives.
The combination of IHC and FISH increased the
number of “targetable” patients by recovering 2
FISHþ cases from the 8 IHC-negative and IP/
WB-positive patients (7/13 cases; 54%).
HER2/neu. This receptor was identified by IP/WB in 6/
14 evaluable cases (43%), all of which were IHC nega-
tive. The lack of any correlation between a gain in
gene copy number and HER2/neu expression suggests
that IP/WB positivity may be due to heterodimer
formation.
Discussion
The aim of this study was to use biochemical analyses
(RTK array cards that can provide an overview of phos-
phorylated RTK in small amounts of total protein
extracts and IP/WB) of cryopreserved material to
demonstrate and validate the presence of a reproducible
panel of activated receptors from mainly the 2 RTK
families of PDGFR and EGFR. We have previously
shown that PDGFRB is activated by means of a ligand-
dependent mechanism;15 we now confirm the PDGFRB
data and show that the pathogenesis of chordoma also
involves EGFR (Table II, IP/WB column, Fig. 2B and C).
The co-expression and co-immunoprecipation of
PDGFRB and EGFR has already been described at the
preclinical level, and it has been demonstrated that
PDGFB stimulates the activation of PDGFRB and sub-
sequently stimulates EGFR unidirectionally.37,38 Our
results demonstrate the co-IP of EGFR and PDGFRB
in surgical specimens and suggest heterodimer for-
mation. If these findings are confirmed, they would
explain the existence of imatinib-insensitive chordomas
which, as they are also addicted for EGFR, can be
expected to escape imatinib treatment. It is interesting
to note in this regard that a response to cetuximab
(an EGFR-specific monoclonal antibody) has been
reported in 2 chordoma patients.39,40
In addition to the interaction between the 2 families,
our co-IP data also indicate the possible existence of het-
erodimerization between individual members of the
EGFR family at least in some cases, as supported by
the finding that the receptor was only bound by a specific
C-terminal antibody, and not by an N-terminal anti-
body. This suggests that the use of bi-specific inhibitors
such as lapatinib, which blocks both EGFR and
HER2/neu,41–43 may offer more clinical benefit than
mono-specific treatments.
Finally, the phospho-RTK-array approach has shown
that other members of the PDGFR family are activated,
including CSF1R and FLT3, which have been reported
to be inhibited by imatinib.44,45
After the upstream RTK analysis, we biochemically
and/or molecularly and cytogenetically investigated
some downstream effectors, and the results indicated
that both the PI3K/AKT and MAPK pathways were acti-
vated in the absence of activating mutations. The co-IP
experiments showed that the p85 subunit of PI3K
directly binds the activated/dimerized PDGFRB recep-
tor and, in line with this, AKT was phosphorylated
(Fig. 3A). Molecular and FISH analyses of the PTEN
oncosuppressor gene showed the absence of inactivating
mutations and the presence of PTEN alterations (mainly
chromosome 10 monosomy) in 7 of 19 cases, although
the latter do not seem to affect protein function
because direct WB did not reveal any difference in the
expression of the phosphatase between the monosomic
and disomic cases (Fig. 3B and C). The WB results
were further confirmed by real-time PCR. We also
detected highly expressed and phosphorylated ERK1
and ERK2 (Fig. 3A), which is consistent with activation
of the EGFR family, in the presence of wild-type KRAS
and BRAF genes (but these 2 markers were not bio-
chemically analyzed). Finally, in line with previously
published data indicating that both AKT and ERK1/2
can activate mTOR, the protein was phosphorylated in
all but 1 case (Fig. 4A), which suggests that it may be
a further “druggable” target.
Taken together, our results show that mTOR acti-
vation is due to the growth factor-mediated activation
of PI3K and MAPK, with no contribution from PTEN.
This means that our findings only partially overlap
those of a recent WB study of the growth-factor
deprived, chordoma-derived U-CHI cell line and IHC
investigations of sporadic sacral chordomas samples,
on the basis of which the authors suggested that
partial or complete PTEN deficiency may be responsible
for mTOR signaling activation.46
Although needing further confirmation, our findings
concerning the 2 regulators of the translational machin-
ery downstream of mTOR raise important speculative
and practical issues. Unlike that in alveolar sarcomas,47
protein synthesis in chordomas seems to be harmonized
by 4E-BP1 rather than S6, and this reinforces the idea
that the translational apparatus may differently regulate
protein production (and thus the cell cycle and tumor
progression) in different histotypes.24 It is currently
believed that the 4E-BP1/eIF4E pathway plays a key
role in tumorigenesis and the 4E-BP1 is a “funnel effec-
tor” that is relevant to prognosis and treatment
response.34 Our finding that the 2 effectors have selec-
tive and histotype-restricted functional roles raise
doubts about the use of the phospho-S6 antibody as a
biomarker for the activation of the PI3K/mTOR
pathway in everyday practice, and indicates a need to
extend the analysis to the phospho-4E-BP1 antibody.
Finally, the low level of S6 activation suggests that S6
may act as an oncosuppressor gene, even if the exper-
imental proof here reported do not indicate any gene
copy loss or any decrease in mRNA levels in the
protein–negative cases.
As previous IHC investigations have shown that
PDGFRB predicts receptor activation in 100% of
cases,15 we analyzed matched FFPE samples for EGFR
and HER2/neu by means of IHC and interphase FISH
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(taking the biochemical results as the gold standard) in
an attempt to acquire insights into identifying patients
who may benefit from targeted EGFR and HER2/neu
treatments. The results indicated that after combining
IHC and FISH (2 techniques that are commonly used
in the case of FFPE material), EGFR sensitivity increases
to 54% without any false positives and so, despite the
constant HER2/neu null immunophenotype (given the
co-expression of EGFR and HER2/neu), this may be
sufficient for patient selection. As HER2/neu is involved
in EGFR dimer formation, its null immunophenotype is
expected and has previously been reported in chordo-
mas. Cumulatively, our results are in agreement with
previously reported IHC data48 for PDGFRB and
Her2/neu, while a lower percentage of positivity was
observed for EGFR. This discrepancy, however, could
be due to the different experimental conditions applied
(different EGFR antibody).
In conclusion, our data indicate new avenues for com-
bining chordoma treatments49 by targeting upstream
and downstream effectors. In addition to the PDGFR
family, which is inhibited by imatinib, the presence of
activated receptors of the EGFR family may provide a
rationale for treating these patients with small molecules
that are effective on both EGFR and HER2/neu.
Moreover, the strong activation of downstream signal-
ing supports the idea that a combination of upstream
TK antagonists and mTOR and MAPK25 inhibitors
could lead to the better control of tumor growth by
avoiding the so-called negative feedback loop,17 lapati-
nib resistance,50 and the PI3K-dependent feedback
loop.25 However, further studies are needed to clarify
the multifaceted regulation of downstream mTOR effec-
tors in different histotypes.
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